**Core Concept**
Insulin therapy is a crucial component of managing diabetes ketoacidosis (DKA), a life-threatening complication of diabetes characterized by hyperglycemia, metabolic acidosis, and ketosis. The choice of insulin for treating DKA is critical, as it affects the rate of recovery and patient outcomes.

**Why the Correct Answer is Right**
Regular insulin is the preferred choice for treating DKA due to its rapid onset of action and short duration of effect, allowing for titration and adjustment of insulin doses as needed. Regular insulin is administered intravenously (IV) to achieve a more predictable and controlled effect. Its rapid onset enables quick reduction of blood glucose levels and correction of metabolic acidosis.

**Why Each Wrong Option is Incorrect**
**Option A:** NPH (Neutral Protamine Hagedorn) insulin is an intermediate-acting insulin, which would be less suitable for DKA management due to its slower onset of action and longer duration of effect, making it difficult to titrate and adjust doses as needed.
**Option B:** Lente insulin is a short-acting intermediate insulin, but it has a slower onset of action compared to regular insulin, making it less ideal for DKA treatment.
**Option C:** Ultra-lente insulin is a long-acting insulin, which would be inappropriate for DKA management due to its prolonged duration of action, leading to unpredictable and potentially prolonged hypoglycemia.

**Clinical Pearl / High-Yield Fact**
When treating DKA, it's essential to monitor blood glucose levels closely and adjust insulin doses frequently to avoid hypoglycemia and ensure rapid correction of metabolic acidosis. Regular insulin is the preferred choice due to its rapid onset and short duration of effect, allowing for precise titration and adjustment of insulin doses.

**Correct Answer:** C. Regular insulin is the preferred choice for treating DKA due to its rapid onset of action and short duration of effect.